Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial
-
- Marc A. Pfeffer
- Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
-
- Brian Claggett
- Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
-
- Eldrin F. Lewis
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University, Palo Alto, CA (E.F.L.).
-
- Christopher B. Granger
- Duke University Medical Center, Durham, NC (C.B.G.).
-
- Lars Køber
- Rigshospitalet, Blegdamsvej, University of Copenhagen, Denmark (L.K.).
-
- Aldo P. Maggioni
- ANMCO Research Center, Florence, Italy (A.P.M.).
-
- Douglas L. Mann
- Washington University School of Medicine, St. Louis, MO (D.L.M.).
-
- John J.V. McMurray
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Scotland (J.J.V.M., M.C.P.).
-
- Jean-Lucien Rouleau
- Montréal Heart Institute, University of Montréal, Quebec, Canada (J.-L.R.).
-
- Scott D. Solomon
- Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
-
- Philippe Gabriel Steg
- Université de Paris, AP-HP (Assistance Publique-Hôpitaux de Paris), FACT (French Alliance for Cardiovascular Trials) and INSERM U-1148, France (P.G.S.).
-
- Otavio Berwanger
- Academic Research Organization – Hospital Israelita Albert Einstein, São Paulo-SP, Brazil (O.B.).
-
- Maja Cikes
- Department of Cardiovascular Diseases, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Croatia (M.C.).
-
- Carmine G. De Pasquale
- Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, Australia (C.G.D.P.).
-
- Alberto Fernandez
- Cardiology Service, Sanatorio Modelo Quilmes, Argentina (A.F.).
-
- Gerasimos Filippatos
- HF Unit at the Attikon University Hospital, Athens, Greece (G.F.).
-
- Karola Jering
- Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
-
- Ulf Landmesser
- Department of Cardiology, Charité University Medicine Berlin, German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin Institute of Health, Germany (U.L.).
-
- Venugopal Menon
- Cardiovascular Medicine, Cleveland Clinic, OH (V.M.).
-
- Béla Merkely
- Semmelweis University, Heart and Vascular Center, Budapest, Hungary (B.M.).
-
- Mark C. Petrie
- Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
-
- Ivo Petrov
- Acibadem City Clinic Cardiovascular Center, Sofia, Bulgaria (I.P.).
-
- Morten Schou
- Department of Cardiology, Herlev-Gentofte University Hospital, Copenhagen, Denmark (M. Schou).
-
- Michele Senni
- Cardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy (M. Senni).
-
- David Sim
- National Heart Centre Singapore (D.S.).
-
- Peter van der Meer
- Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (P.v.d.M.).
-
- Martin Lefkowitz
- Novartis Pharmaceutical Corporation, East Hanover, NJ (M.L., Y.Z., Y.W.).
-
- Yinong Zhou
- Novartis Pharmaceutical Corporation, East Hanover, NJ (M.L., Y.Z., Y.W.).
-
- Yi Wang
- Novartis Pharmaceutical Corporation, East Hanover, NJ (M.L., Y.Z., Y.W.).
-
- Eugene Braunwald
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA (E.B.).
収録刊行物
-
- Circulation
-
Circulation 145 (1), 87-89, 2022-01-04
Ovid Technologies (Wolters Kluwer Health)